WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
BioRestorative Therapies, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its BRTX-100 program for treating chronic lumbar disc disease (cLDD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results